Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Chan

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|August 9, 2014
Assessment of the effect of ofatumumab on cardiac repolarizationRoxanne C Jewell, Kevin Laubscher, Eric Lewis, et al.
Experimental Eye Research|March 10, 2022
Anti-retinal IgG antibodies in patients with early and advanced type 2 macular telangiectasiaSamuel McLenachan, Chandrakumar Balaratnasingam, Rachael C Heath Jeffery, et al.
Leukemia & Lymphoma|February 28, 2015
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemiaWilliam Nigel Patton, Robert Lindeman, Andrew C Butler, et al.
Acupuncture in Medicine : Journal of the British Medical Acupuncture Society|November 28, 2009
A prospective randomised controlled study on efficacies of acupuncture and steroid in treatment of idiopathic peripheral facial paralysisFu Man Tong, Shun Kit Chow, Patrick Yiu Bong Chan, et al.
Cancer Science|May 31, 2017
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesYosuke Minami, Hironobu Minami, Toshihiro Miyamoto, et al.
Clinical & Experimental Ophthalmology|July 6, 2026
Australian and New Zealand Glaucoma Society (ANZGS) Consensus on Interventional GlaucomaGraham A Lee, Lance Liu, Ridia Lim, et al.
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|August 9, 2014
Assessment of the effect of ofatumumab on cardiac repolarizationRoxanne C Jewell, Kevin Laubscher, Eric Lewis, et al.
Experimental Eye Research|March 10, 2022
Anti-retinal IgG antibodies in patients with early and advanced type 2 macular telangiectasiaSamuel McLenachan, Chandrakumar Balaratnasingam, Rachael C Heath Jeffery, et al.
Leukemia & Lymphoma|February 28, 2015
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemiaWilliam Nigel Patton, Robert Lindeman, Andrew C Butler, et al.
Acupuncture in Medicine : Journal of the British Medical Acupuncture Society|November 28, 2009
A prospective randomised controlled study on efficacies of acupuncture and steroid in treatment of idiopathic peripheral facial paralysisFu Man Tong, Shun Kit Chow, Patrick Yiu Bong Chan, et al.
Cancer Science|May 31, 2017
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesYosuke Minami, Hironobu Minami, Toshihiro Miyamoto, et al.
Clinical & Experimental Ophthalmology|July 6, 2026
Australian and New Zealand Glaucoma Society (ANZGS) Consensus on Interventional GlaucomaGraham A Lee, Lance Liu, Ridia Lim, et al.
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Pageof 5